
























Chromatin regulation in embryonic stem cells 
 
Since its birth, epigenetics has been closely linked to 
development and differentiation [1].  Epigenetic 
processes are the main elements responsible for 
generating many distinct specialized cell populations 
from a single, undifferentiated cell.  The first few cells 
in a zygote must be able to expand themselves (defined 
as self-renewal) while retaining the potential to give rise 
to any differentiated adult cell (defined as pluripotency 
for the inner cell mass and derived embryonic stem cells 
- ESC).  To achieve this potency, germ cell epigenetic 
states must be reset, and the zygotic genome must be 
activated to allow expression of appropriate genes in 
subsequent development [2,3]. 
 
When a differentiation step is to be initiated, a cell must 
modify its gene expression program to change its 
phenotype.  ESC are thought to have a globally open 
chromatin structure that keeps pluripotency 
maintenance genes active and differentiation genes 
silenced, in a reversible, highly plastic way [4].   
Following differentiation towards a definite lineage, a 
stem cell must downregulate pluripotency genes 
definitively, activate expression of genes for the 
necessary differentiation phenotype, and lock 




























Moreover, these processes must be precisely regulated 
in space and time. 
 
These skills are conferred on a stem cell mainly by the 
action of the epigenetic machinery.  Specific histone 
marks and enzymes responsible for their establishment 
have been identified as central to ESC pluripotency and 
differentiation; these processes are based principally on 
the interplay of a web of key transcription factors and 
chromatin-modifying enzymes.  Silencing of 
developmental genes is achieved, at least in part, 
through the creation of chromatin domains, termed 
“bivalent”, that contain overlapping regions of the 
transcriptionally permissive histone modification 
H3K4me3 and the silencing mark H3K27me3 [5].   
Bivalent domains maintain silencing of 
developmentally important genes while simultaneously 
keeping them poised for either definitive repression or 
activation, depending on the developmental lineage for 
which the ESC are destined.  In essence, this bivalent 
configuration is thought to enable retention of 
developmental plasticity by these genes. 
 
Many other mechanisms are involved in the 
establishment of the stem cell epigenetic landscape [6].  
Despite the large amount of information available on 
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Global acetylation of H3K9 increases during mESC and 
hESC (mouse and human) spontaneous differentiation 
to fibroblasts [7], whereas this residue loses acetylation 
during retinoic acid-induced endoderm-like 
differentiation of hESC [8].  The role of histone 
acetyltransferase (HAT) and deacetylase (HDAC) 
complexes in pluripotency maintenance and ESC 
differentiation remain only partially defined.  The 
Sin3A-HDAC complex has a positive role in mESC 
pluripotency maintenance [9], whereas HDAC1 deletion 
in mESC leads to reduced activity of Sin3A, NuRD, and 
CoREST corepressor complexes; this affects only ESC 
differentiation, without impairing stemness or 
proliferation [10].  Although HAT p300 deletion does 
not affect self-renewal in undifferentiated mESC, it 
causes abnormal marker expression when 
differentiation is induced [9]. 
 
SirT1, an old multi-faceted enzyme with a new role 
in pluripotency 
 
Sirtuins are class III HDAC, paralogues of the yeast 
enzyme Sir2.  They are characterized by their 
requirement for NAD
+ as a cofactor, which links sirtuin 
activity to the cell redox state and metabolism.  Sirtuin-
compacted chromatin is characterized by histone lysine 
hypoacetylation [11]; hypoacetylation of H4K16 is the 
signature of Sir2 silencing [12,13].  In addition to 
epigenetic silencing, sirtuins have a role in various 
chromatin-related processes, including DNA repair, 
recombination and DNA replication [14,15]. 
 
Mammals have seven sirtuin family proteins, termed 
SirT1 to -7.  SirT1, the best studied to date, has been 
implicated in processes as varied as metabolism, 
differentiation, cancer, stress response and cell 
senescence.  Although SirT1 mutant mice generated by 
various targeting strategies and on different genetic 
backgrounds have distinct phenotypes, most of the in 
vivo data suggest that Sirt1 acts in early development 
[16,17,18].  This role nonetheless is unlikely to be 
essential, since most Sirt1 knockout (KO) mice pass 
through early embryonic stages, and in some cases 
reach adulthood; SirT1 might instead have a modulatory 
effect on basic developmental processes.  In mESC, 
Sirt1 impedes p53 nuclear translocation in response to 
mild oxidative stress; Sirt1 downregulation allows 
acetylated p53 to enter the nucleus and inhibit Nanog 
expression, causing differentiation [19].  Nerve tissue 
differentiation is likewise dependent on metabolic 
changes and is regulated by SirT1.  Under oxidative 
stress, mouse neural precursor cells stop proliferating 
and differentiate into astroglial cells (rather than 
neurons) through a SirT1-dependent mechanism that 
relies on Hes1 modulation and direct silencing of the 
Mash1 promoter [20].  In skeletal muscle and adipose 
tissue, SirT1 upregulation after fasting induces silencing 
of certain key genes to inhibit differentiation.  In 
myocytes, myogenin and myosin heavy chain (MHC) 
genes are silenced by SirT1 through the binding and 
deacetylation of MyoD and the PCAF (p300/CBP 
associating factor) [21].  In adipocytes, SirT1 inhibits 
activation of genes such as fatty acid-binding protein 
(aP2) through recruitment of the corepressors NCoR 
and SMRT to the PPARgamma-response genes [22]. 
 
SirT1 as a hESC differentiation modulator 
 
Recent work from our lab shows that SirT1 is also 
strongly expressed in hESC.  We demonstrated that 
SirT1 downregulation is necessary to establish correct, 
specific differentiation programs during human and 
mouse ESC differentiation, because SirT1 binds to and 
epigenetically represses a subset of developmental 
genes in pluripotent hESC.  This enzyme exerts its 
repressive action on promoters, maintaining H4K16 and 
H4K9 deacetylated in hESC; its fine-tuned 
downregulation during differentiation contributes to 
epigenetic reactivation of these genes [23].  It is 
possible that SirT1 works in the context of a larger 
epigenetic modification complex, as demonstrated in 
the murine Polycomb repressive complex 4 (PRC4) 
[24].  Some of these SirT1-regulated genes have long 
been recognized as key factors in neuro-retinal 
morphogenesis, and their misregulation in the absence 
of SirT1 could account for the specific phenotype of the 
KO mice, which particularly affects ectodermal 
patterning.  As predicted by the ability of the KO mice 
to pass through the first differentiation steps, and 
similar to reports for other HDAC, SirT1 does not 
appear to be essential in hESC pluripotency, as its 
depletion in these cells does not in itself induce 
differentiation or result in downregulation of 
pluripotency markers.  In mouse ESC and at difference 
from human ESC, SirT1 depletion determines a mild 
negative effect on pluripotency gene expression.  More 
importantly, Sirt1 overexpression leads to greater 
pluripotency gene expression, which is sustained 
throughout the first differentiation steps.  We none-
theless showed that this role of SirT1 is mostly indirect, 
and is probably mediated through its effect on 
developmental genes or through other SirT1 targets, 
such as p53 acetylation [17,19,23].  The importance of 
the precise time course of SirT1 downregulation for 
correct differentiation is also highlighted by the fine 
mechanisms that modulate its expression.  In our study, 
we showed that SirT1 downregulation during hESC 
differentiation depends at least in part on CARM1.  This 
arginine methyl-transferase helps to maintain 
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histone methylation at the promoters of specific 
pluripotency genes [25,26].  We demonstrated that it 
also indirectly regulates differentiation genes by 
methylating the RNA-binding protein HuR, determining 
its binding and the stabilization of the SirT1 transcript.  
CARM1 downregulation has thus a dual role: it acts 
directly on pluripotency genes by regulating chromatin 
structure and indirectly by priming developmental genes 
through SirT1 downregulation.  As suggested by the 
distinct kinetics of mRNA and protein downregulation, 
SirT1 decrease is probably modulated at more than one 
level.  In mice, SirT1 protein levels are downregulated 
during mESC differentiation through the miR-9 
upregulation that directly inhibits its translation [27].   
This indicates that various mechanisms have evolved, 
probably with distinct relevance in different species, to 
ensure correct SirT1 downregulation soon after 
differentiation triggering. 
 
Linking SirT1 as a developmental gene repressor to 
cancer 
 
SirT1 has long been attributed a role in cancer.  The 
debate nonetheless remains active regarding its role as an 
oncogene or tumor suppressor.  This controversy is based 
on studies of SirT1 expression in cancer and on its wide 
range of functions, including its activity on well-known 


























inducer, SirT1 would better fit the definition of an 
oncogene; for instance, p53 deacetylation and 
downregulation prolong survival, which could promote 
cancer initiation in proliferating cells through apoptosis 
escape [29].  SirT1 is overexpressed in many tumor types 
including prostate, colon, leukemia, and lymphoma 
[30,31,32,33]. In tumor cells, Sirt1 is located in the 
promoter of densely hypermethylated tumor suppressor 
genes (E-cadherin, MLH1, GATA-4, GATA-5 and p27) 
and contributes to their transcriptionally inactive state 
[34]. 
 
In contrast to these observations, and as SirT1 is 
considered important in organism survival, a tumor 
suppressor function might be also anticipated.  In support 
of this theory, Sirt1 overexpression in ApcMin/+ mice 
induces beta-catenin deacetylation, reducing colon tumor 
formation [35]; in addition, both genetic and drug-
induced Sirt1 activation inhibit growth and/or induce 
apoptosis in certain cancer models [18,30].  SuperSirt1 
mice were recently generated, which have moderate Sirt1 
overexpression (a ~3-fold increase); they are apparently 
phenotypically indistinguishable from WT mice but show 
metabolic differences, with increased energy expenditure 
and lower lipid-induced inflammation, leading to 
protection from hepatic steatosis [36].  Aged SuperSirt1 
mice show lower DNA damage levels, are generally 
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developmental genes might not be merely an additional 
piece in the developmental epigenetic puzzle.  Intense 
studies of sirtuins led to the development of many small 
molecule modulators to activate or inhibit their activity.  
The application of SirT1 inhibitors centers mainly on 
cancer therapy.  Sirtinol and some of its derivatives 
arrest cell cycling in breast and lung cancer [38].  Both 
cambinol and tenovins also inhibit cancer growth and 
induce apoptosis [39].  Salermide treatment leads to 
growth arrest and a pronounced apoptotic effect in 
various cancer cell lines, without affecting a non-
cancerous fibroblast line [40].  The discovery of a SirT1 
function in suppressing developmental genes could be a 
further clue for the correct interpretation its role in 
cancer.  As neoplastic cells are thought to recapitulate 
many stem cell characteristics [41], the oncogenic 
function of Sirt1 might also be mediated by aberrant 
regulation of developmental genes, especially for those 
cancers in which the undifferentiated phenotype 
predominates. 
 
SirT1 and senescence 
 
An interesting role ascribed to Sir2 involves increased 
replicative lifespan, the number of cell divisions in which 
a mother cell can engage in its life [12].  In the worm 
Caenorhabditis elegans, in Drosophila melanogaster and 
possibly in mammals, Sir2 family members are also 
involved in extending lifespan [42,43].  One proposed 
mechanism to explain the relationship between Sir2 and 
lifespan is caloric restriction (CR), which increases 
lifespan in organisms from yeast to mammals [12].  CR 
produces a more oxidative metabolic state, reflected by 
high levels of NAD
+.  This in turn activates sirtuins and 
facilitates survival mechanisms such as senescence and 
apoptosis inhibition or activation of stress response 
pathways [44]. 
 
Although a mechanistic link between cell senescence 
and aging is lacking, the implication of SirT1 in 
longevity and cell senescence of most organisms 
suggests an important role in the aging process.  A cell 
is considered senescent either when it reaches growth 
arrest owing to telomere consumption (replicative 
senescence) or when abnormal oncogene expression 
alters cell physiology (premature senescence) [45].   
Data supporting a role for SirT1 in cell senescence are 
still correlative; senescent fibroblasts show a decrease 
in SirT1 expression [46] and SirT1 overexpression can 
inhibit oncogene-induced senescence as a result of 
direct p53 deacetylation, which counteracts p53 
hyperacetylation in oncogene-induced senescence [47].  
Many other observations support this idea, and other 
lines of investigation suggest an even more general role 
for SirT1 in aging and longevity [48]. 
 
Given the effects of SirT1 on longevity, rejuvenation 
and in counteracting aging, the pharmaceutical, 
“nutraceutical” and cosmetic industries are interested in 
the development of small molecule SirT1 activators 
[49,50].  Resveratrol, a natural compound present in 
traces in some red wines, has a strong sirtuin-activating 
effect.  This polyphenol and related synthetic molecules 
have anti-aging activity and positive effects on aging-
related disease, prolonging survival in mice [42,51,52].  
Clinical trials are under way to test the therapeutic 
potential of sirtuin activators in conditions such as type 
2 diabetes [53]. 
 
One of the more intriguing hypotheses about aging and 
age-related disease is that age-associated phenotypic 
alterations derive from the inability of resident stem 
cells to maintain tissue structure and function [54].   
This, and our current understanding of cell senescence 
as summarized above, suggest that the aging process 
could arise from loss or misfunction of self-renewal 
and/or differentiation potential in adult stem cell 
populations.  Our data show a positive role for SirT1 in 
stemness by aiding in the silencing of differentiation 
genes, which suggests new potential explanations of its 
ability to extend lifespan and to avoid cell and organism 
senescence.  SirT1 might in fact contribute to 
maintaining a “stemness-like” status in cell populations 
involved in tissue regeneration and to orchestrating their 
correct differentiation within tissue. 
 
Although there is still a long path to walk before we 
reach full understanding of the complex and intriguing 
role of sirtuins, a small step has been made towards 
comprehension of SirT1 function in stem cells, with 
possible implications for the related fields of cancer and 
aging (Figure 1).  There is hope for a solution of present 
controversies, for new hypotheses, and for more fruitful 
application of this knowledge to cancer therapy, anti-
aging and regenerative medicine, to improve the quality 
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